Cerenome Inc. (CNSY)

Profile

https://plustherapeutics.com

Cerenome, Inc. is a central nervous system oncology company focused on improving detection and treatment of cancers affecting the brain and spinal cord. The company operates an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence-driven data analytics to address complex CNS malignancies. Its activities span the development and commercialization of radiotherapeutic drugs for rare and difficult-to-treat cancers, including recurrent glioblastoma and other CNS tumors, as well as solid organ cancers such as primary and secondary liver cancers. Cerenome also offers specialized laboratory-developed tests, notably the CNSide assay, designed to identify tumor cells that have metastasized to the central nervous system in patients with systemic cancers. By linking advanced diagnostics with innovative therapeutic modalities, Cerenome plays a distinct role in the healthcare and biotechnology sectors, targeting areas of high unmet medical need in oncology. The company is headquartered in Houston, Texas and operates today as a clinical-stage enterprise serving providers and patients involved in CNS cancer care.